COPD is a progressive and life-threatening respiratory disease without a cure. It is the third leading cause of death globally, according to the World Health Organization. The condition damages the airways and the lungs, leading to debilitating breathlessness that has a devastating impact on performing basic daily activities such as getting out of bed, showering, eating and walking. This study is for people with COPD.
Study Name is "ENHANCE"
ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) Phase 3 trials
Volunteers needed for a 24 week long clinical trial with up to 5 office visits for treatment. Stipend available up to $554.00.
To Qualify, you must meet the following INCLUSION CRITERIA:
1.) 40 to 80 Years of Age
2.) Have a COPD Diagnosis
3.) Capable of using a nebulizer
4.) Current -or- Former Cigarette Smoking History
To Qualify, you must NOT meet the following EXCLUSION CRITERIA:
1.) Positive Covid-19 test at screening
2.) Lung surgery within the last 1 year
3.) Oxygen Therapy use over 12 hours per day
4.) COPD Exacerbation within 3 months (requiring oral steroids)
ClinicalTrials.gov Identifier:
NCT 4542057
https://clinicaltrials.gov/ct2/show/NCT04542057?term=rpl554-co-302&draw=2&rank=1
We love our patients, so feel free to visit during normal business hours.
Mon | 09:00 am – 05:00 pm | |
Tue | 09:00 am – 05:00 pm | |
Wed | 09:00 am – 05:00 pm | |
Thu | 09:00 am – 05:00 pm | |
Fri | 09:00 am – 05:00 pm | |
Sat | Closed | |
Sun | Closed |
Copyright © 2022 Principle Research Solutions,llc - All Rights Reserved.
Your One-Stop Research SOLUTION